Radiopharm Theranostics Limited (RDPTF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Peers in Healthcare
Radiopharm Theranostics Limited has no peer companies in this window.
Recent press releases
Radiopharm Theranostics Limited has not issued a press release in this window.
SEC filings
All filings →Radiopharm Theranostics Limited has not filed an SEC document in this window.
Insider trades
All insider trades →Radiopharm Theranostics Limited has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Radiopharm Theranostics Limited
All people →No officers or directors have been indexed for Radiopharm Theranostics Limited.